Search
Enanta Pharmaceuticals Inc
ENTAAdd to Watchlist
12.200USD
-0.320-2.56%
Close 09-17 16:00（ET）
355.56MMarket Cap
LossP/E TTM
Enanta Pharmaceuticals Inc (ENTA) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to Enanta Pharmaceuticals Inc in the past month.
Buy
2 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
22.400USD+82.26%
ENTA Analyst Recommendation Trends
In the current month, ENTA has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ENTA average Analyst price target in the last month is 22.400.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
2
2
2
2
2
2
2
2
4
4
4
4
5
5
5
5
0
0
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
7
7
8
8
8
8
ENTA Analyst Rating for Peer Comparison
Updated: Sep 17, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
7
17
12
1
0
37
Amgen Inc
AMGN
4
12
18
2
1
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Pfizer Inc
PFE
5
6
19
1
1
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Financial Forecasting
Based on analysts' estimates, ENTA EPS is projected to reach -0.783 in FY2026Q4, following reported EPS of -0.670 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.81
-0.49
-0.51
-0.78
-0.48
Actual
-0.42
-0.45
-0.67
--
--
Surprise
+48.57%
+7.62%
-31.45%
--
--
FAQs
What is Enanta Pharmaceuticals Inc's expected revenue for the next quarter?
Enanta Pharmaceuticals Inc's expected revenue is 14.20M.
What is Enanta Pharmaceuticals Inc's price target?
Analysts forecast that Enanta Pharmaceuticals Inc's price target is USD 22.40, with the highest forecast at USD 32.00 and the lowest forecast at USD 20.00.
How have Enanta Pharmaceuticals IncENTA's recent earnings per share performed?
The market expectation was USD -0.67, while Enanta Pharmaceuticals IncENTA's earnings per share (EPS) for the previous quarter was USD -0.45. EPS for the next quarter is expected at USD -0.78.
What is the analyst rating for Enanta Pharmaceuticals Inc?
Based on the ratings of Enanta Pharmaceuticals Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.